Testosterone Replacement Therapy

References

• Applebaum-Bowden D, Haffner S M, Hazzard W R. The dysproteinemia of anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in high-density lipo-protein2 -cholesterol. Metabolism 1987; 36: 942–952
   Web of Science ®Google Scholar
• Arver S, Dobs A S, Meikle A W, Allen R P, Sanders S W, Mazer N A. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 1996; 155: 1604–1608
   PubMed Web of Science ®Google Scholar
• Bagatell C J, Knopp R H, Bremner W J. Androgen effects on plasma lipids in men. Curr Top Androl 1993; 138–143
   Google Scholar
• Balds-Pratsch M, Langer K, Place V A, Nieschlag E. Substitution therapy of hypogonadal men with transdermal testosterone over one year. Acta Endocrinol (Copenh) 1988; 118: 7–13
   PubMedGoogle Scholar
• Balds-Pratsch M, Yoon Y D, Knuth U A, Nieschlag E. Transdermal testosterone substitution therapy for male hypogonadism. Lancet 1986; 25: 943–945
   Google Scholar
• Barret-Connor E, Laskso M. Ischemic heart disease risk in postmenopausal women. Arteriosclerosis 1990; 10: 531–534
   PubMedGoogle Scholar
• Behre H M, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (OxF) 1994; 40: 341–349
   PubMed Web of Science ®Google Scholar
• Behre H M, Nieschlag E. Testosterone buciclate(20Aett-l) in hypogonadal men: pharma-cocinetics and pharmacodynamics of the new long-acting androgen ester. J Clin Endocrinol Metab 1992; 75: 1204–1210
   PubMed Web of Science ®Google Scholar
• Berglund L, Carlstrom K, Stege R, Gottlieb C, Eriksson M, Angelin B O, Henriksson P. Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males. J Clin Endocrinol Metab 1996; 81: 2633–2637
   PubMed Web of Science ®Google Scholar
• Berry S J, Coffey D S, Walsh P C, Edwing L L. The development of benign prostatic hyperplasia with age. J Urol 1984; 132: 474–479
   PubMed Web of Science ®Google Scholar
• Bertelloni S, Baroncelli G I, Battini R, Perrii G, Saggese G. Short-term effect of testosterone treatment on reduced bone density in boys with constitutional delay of puberty. J Bone Miner Res 1995; 10: 1488–1495
   PubMed Web of Science ®Google Scholar
• Bhasin S, Beemner W J. Clinical Review 85: emerging issues in androgen replacement therapy. J Clin Endocrinol Metab 1997; 82: 3–8
   PubMed Web of Science ®Google Scholar
• Bhasin S, Storer T W, Berman N, Yarasheski K E, Clevenger B, Phillips J, Lee W P, Bunnell T J, Casaburi R. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 407–413
   PubMed Web of Science ®Google Scholar
• Bhasin S, Swedloff R S, Steiner B S, Galmarini M, Pandian M R, Berman N. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10–11 weeks in hypogonadal men. J Clin Endocrinol Metab 1992; 74: 75–83
   PubMed Web of Science ®Google Scholar
• Bremner W J, Vitiello M V, Prinz P M. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983; 56: 1278–1281
   PubMed Web of Science ®Google Scholar
• Brodsky I G, Balagopal P, Nair K S. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3469–3475
   PubMed Web of Science ®Google Scholar
• Burris A S, Banks S M, Carter C S, Davidson J M, Sherins R J. A long-term, prospective study of the physiological and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl 1992; 13: 297–304
   PubMedGoogle Scholar
• Casaburi R, Goren S, Bhasin S. Substantial prevalence of low anabolic hormone levels in COPD patients undergoing rehabilitation. Am J Respir Crit Care Med 1996; 4: A128
   Google Scholar
• Crilly R G, Francis R M, Nordin B EC. Steroid hormones, ageing and bone. J Clin Endocrinol Metab 1989; 10: 115–139
   Google Scholar
• Cunningham G R, Cordero E, Thornby J I. Testosterone replacement with transdermal therapeutic system. JAMA 1989; 261: 2525–2530
   PubMed Web of Science ®Google Scholar
• Davidson J M, Camargo C A, Smith E R. Effects of androgens on sexual behaviour of normal men. J Clin Endocrinol Metab 1979; 57: 557–562
   Google Scholar
• Deslypere J P, Vermeulen A. Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab 1984; 59: 955–962
   PubMed Web of Science ®Google Scholar
• Deslypere J P, Vermeulen A. Influence of age on steroid concentrations in skin and striated muscle in women and cardiac muscle and lung tissue in men. J Clin Endocrinol Metab 1985; 60: 648–653
   Google Scholar
• Dluhy R G. The growing spectrum of HIV-related endocrine abnormalities. J Clin Endocrinol Metab 1990; 79: 563–565
   Google Scholar
• Douglas T H, Connelli R R, McLeod D G, Erickson S J, Barren R, III, Murphy G P. Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men. J Surg Oncol 1995; 59: 246–250
   PubMed Web of Science ®Google Scholar
• Finkelstein J S, Klibanski A, Neer R M, Greenspan S L, Rosenthal D I, Crowley W F. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Inter Med 1987; 106: 354–361
   PubMed Web of Science ®Google Scholar
• Forbes G B, Porta C R, Herr B, Griggs R C. Sequence of changes in body composition induced by testosterone and reversal of changes after the drug is stopped. JAMA 1992; 267: 397–399
   PubMed Web of Science ®Google Scholar
• Friedel K E, Hannan C J, Jones R E, et al. High-density lipoprotein is not decreased if an aromatizable androgen is administered. Metabolism 1990; 39: 69–77
   PubMed Web of Science ®Google Scholar
• Glodray D, Weisman Y, Jaccar N, Merdler C, Chen J, Matzmatzkin H. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab 1993; 76: 288–290
   PubMed Web of Science ®Google Scholar
• Godsland I F, Wynn V, Crook D. Sex, plasma lipoproteins, and atheroesclerosis: prevailing assumptions and outstanding questions. Am Heart J 1987; 114: 1467–1503
   PubMed Web of Science ®Google Scholar
• Goldberg R B, Rabin D, Alexander A N, Doelle G C, Getz G S. Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apoproteins-A-I and B. J Clin Endocrinol Metab 1992; 116: 967–973
   Google Scholar
• Goldman J A, Wajchenberg B L, Liberman B, Nery M, Achando S, Germek O A. Contrast analysis for the evaluation of the circadian rhythms of plasma Cortisol, androstenedione, and testosterone in normal men and the possible influence of meals. J Clin Endocrinol Metab 1985; 60: 164–167
   PubMed Web of Science ®Google Scholar
• Gooren L JG. The age-related decline of androgen levels in men: clinically significant. Br J Urol 1996; 78: 763–768
   PubMedGoogle Scholar
• Gray A, Feldman H A, McKinlay J B, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusset male aging study. J Clin Endocrinol Metab 1991; 73: 1016–1025
   PubMed Web of Science ®Google Scholar
• Griffin J E, Wilson J D. Disorders of the testes and the male reproductive tract. Williams Textbook of Endocrinology, J D Wilson, D W Foster. W.B. Saunders, Philadelphia 1992; 799–852
   Google Scholar
• Griggs R C, Kingston W, Josefowicz R F, Hen B E, Forbes G, Halliday D. Effect of testosterone on muscle mass and muscle mass synthesis. Am J Appl Physiol 1989; 66: 498–503
   PubMed Web of Science ®Google Scholar
• Grinspoon S K, Bilezikian J P. HIV disease and the endocrine system. N Engl J Med 1992; 327: 1360–1365
   PubMed Web of Science ®Google Scholar
• Guess H A. Benign prostatic hyperplasia: antecedent and natural history. Epidemiol Rev 1992; 14: 131–153
   PubMed Web of Science ®Google Scholar
• Guo C Y, Jones T H, Eastell R. Treatment of a isolated hypogonadotropic hypogonadism: effect on bone mineral density and bone turnover. J Clin Endocrinol Metab 1997; 82: 658–665
   PubMed Web of Science ®Google Scholar
• Haffner S M, Mykkanen L, Valdez R H. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 1993; 77: 1610–1615
   PubMed Web of Science ®Google Scholar
• Handelsman D J, Conway A J, Boylan L M. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 1990; 71: 216–222
   PubMed Web of Science ®Google Scholar
• Harman S M, Tsitouras P D. Reproductive hormones in aging men, I: measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. J Clin Endocrinol Metab 1980; 51: 35–40
   PubMed Web of Science ®Google Scholar
• Henderson J T, Richmond J, Sumerling M D. Androgenic-anabolic steroid therapy and hepatocellular carcinoma. Lancet 1973; 1: 934
   PubMed Web of Science ®Google Scholar
• Holmäng S, Marin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate 1993; 23: 99–106
   PubMed Web of Science ®Google Scholar
• Horowitz M, Wishart J M, O'Loughlim P D, Morris H A, Need A G, Nordin B EC. Osteoporosis and Klinefelter's syndrome. Clin Endocrinol (Oxf) 1992; 36: 113–117
   PubMed Web of Science ®Google Scholar
• Hromadova M, Hacik T, Malatinsky E, Riecansky I. Alterations of lipid metabolism in men with hypotestosteronemia. Horm Metab Res 1991; 23: 392–394
   PubMed Web of Science ®Google Scholar
• Jackson J A, Kleerekoper M, Parfidd A M, Rao A S, Villanueva A R, Frame B. Bone hystomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab 1987; 65: 53–58
   PubMed Web of Science ®Google Scholar
• Jockenhovel F, Vogel E, Kreutzer M, Rheinhardt W, Lederbogen S, Reinwein D. Pharmacokinetics and pharmacodynamis of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol 1996; 45: 61–71
   PubMed Web of Science ®Google Scholar
• Knopp R H. Estrogen replacement therapy for reduction of cardiovascular risk in women: estrogen replacement therapy for reduction of cardiovascular risk in women. Curr Opin Lipidol 1991; 2: 240–247
   Google Scholar
• Kubler A, Schulz G, Cordes D, Bayer J, Krause U. The influence of testosterone substitution on bone mineral density in patients with Klinfelter's syndrome. Exp Clin Endocrinol 1992; 100: 129–132
   PubMedGoogle Scholar
• Kushwaha R S. Female sex steroid hormones and lipoprotein metabolism. Curr Opin Lipidol 1991; 3: 167–172
   Google Scholar
• Kwan M, Greenleaf W J, Mann J, Crapo L, Davidson J M. The nature of androgen action on male sexuality: a combined laboratory self-report study on hypogonadal men. J Clin Endocrinol Metab 1983; 57: 557–562
   PubMed Web of Science ®Google Scholar
• Lejeune-Lenain C, VanCauter E, Desir D, Beyloos M, Franckson J RM. Control of circadian and episodic variations of adrenal androgens secretion in man. J Endocrinol Invest 1987; 10: 267–276
   PubMed Web of Science ®Google Scholar
• Lobo R A. Estrogen and cardiovascular disease. Ann NY Acad Sci 1990; 592: 286–294
   PubMed Web of Science ®Google Scholar
• Luke M C, Coffey D S. The male sex accessory tissues: structure, androgen action and physiology. The Physiology of Reproduction, 2d ed, E Knobil, J D Neill. Raven, New York 1994; 1435–1487
   Google Scholar
• Marin P, Krotkiewski M, Bjomtorp P. Androgen treatment of middle-aged, obese men: effects of metabolism, muscle and adipose tissues. Eur J Med 1992; 1: 329–336
   PubMedGoogle Scholar
• Martin K A, Freeman M W. Postmenopausal hormone-replacement therapy (Editorial). N Engl Med 1993; 328: 1115–1117
   PubMed Web of Science ®Google Scholar
• Matsumoto A M. Hormonal therapy of male hypogonadism. Clin Androl 1994; 23: 857–875
   Google Scholar
• Mc Neal J E. Anatomy of the prostate and morphogenesis of BPH. Prog Clin Biol Res 1984; 145: 27–53
   PubMedGoogle Scholar
• Meikle A W, Arver S, Dobs A S, Adolfsson J, Sanders S W, Middleton R G, Stephenson R A, Hoover D R, Rajadam L, Mazer N A. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 1997; 49: 191–196
   PubMed Web of Science ®Google Scholar
• Meikle A W, Arver S, Dobs A S, Sanders S W, Mazer N A. Androderm: a permeation enhanced non-scrotal testosterone transdermal system for the treatment of male hypogonadism. Pharmacology, Biology, and Clinical Applications of Androgens, S Bhasin, H L Gabelnick, J M Spieler, R S Swerdloff, C Wang. Wiley-Liss, New York 1995; 449–457
   Google Scholar
• Meikle A W, Arver S, Dobs A S, Sanders S W, Rajaram L, Mazer N A. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site. J Clin Endocrinol Metab 1996; 81: 1832–1840
   PubMed Web of Science ®Google Scholar
• Meikle A W, Mazer N A, Moellmer J F, Stringham J D, Tolman K G, Sanders S W, Odell W D. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 1992; 74: 623–628
   PubMed Web of Science ®Google Scholar
• Mendoza S, Velazquez E, Osona A, Hamer T, Glueck C J. Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein (a). J Lab Clin Med 1994; 123: 837–841
   PubMed Web of Science ®Google Scholar
• Mitchell R, Hollis S, Rothweil C, Robertson R. Age-related changes in the pituitary-testicular axis in normal men: lower serum testosterone results from decreased bioactive drive. Clin Endocrinol 1995; 42: 501–507
   PubMed Web of Science ®Google Scholar
• Morales A, Heaton J PC. Comments of medical therapy with emphasis on the treatment of hypogonadal states. Int J Impot Res 1993; 5: 253–258
   Google Scholar
• Morales A, Johnston B, Heaton J PW, Lundie M. Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J Urol 1997; 157: 849–854
   PubMed Web of Science ®Google Scholar
• Morley J E, Kaiser F E. Sexual function with advancing age. Med Clin North Am 1989; 73: 1483–1495
   PubMed Web of Science ®Google Scholar
• Morley J E, Perry H M, III, Kaiser F E, Kraenzle D, Jensen J, Houston K, Mattammal M, Perry H M, Jr. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41: 149–152
   PubMed Web of Science ®Google Scholar
• Muta K, Kato K-I, Akamure K. Age-related changes in the feedback regulation of gonadotropin secretion by sex steroids in men. Acta Endocrinol 1981; 96: 154–162
   PubMedGoogle Scholar
• O'Carroll R, Shapiro C, Bancroft J. Androgens, behaviour and nocturnal erection in hypogonadal men: the effects of varying the replacement dose. Clin Endocrinol (Oxf) 1985; 23: 527–538
   PubMed Web of Science ®Google Scholar
• Ozata M, Yildirimkaya M, Bulur M, Yilmaz K, Bolu E, Ahmet C, Gundogan A. Effects of gonadotropin and testosterone treatments on lipoprotein, high-density lipoprotein particles, and other lipoprotein levels in male hypogonadism. J Clin Endocrinol Metab 1996; 81: 3372–3378
   PubMed Web of Science ®Google Scholar
• Partsch C J, Weinbauer G F, Fang R, Nieschlag E. Injectable testosterone undecanoate has more favorable pharmacokinetics and pharmacodynamics than testosterone enanthate. Eur J Endocrinol 1995; 132: 514–519
   PubMed Web of Science ®Google Scholar
• Place V A, Attkinson L, Prather D A, Trunnell N, Yates F E. Transdermal testosterone replacement through genital skin. Testosterone: Action, Deficiency, Substitution, E Nieschlag, H M Behre. Springer, Heidelberg 1990; 165–181
   Google Scholar
• Rosner W. Plasma steroid-binding proteins. Endocrinol Metab Clin North Am 1991; 4: 697–720
   Google Scholar
• Salehian B, Wang C, Alexander G, Davidson T, McDonald V, Berman N, Dudley R E, Ziel F, Swerdloff R S. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate. J Clin Endocrinol Metab 1995; 80: 3567–3575
   PubMed Web of Science ®Google Scholar
• Sasagawa I, Nakada T, Kazama T, Terada T, Katayama T. Testosterone replacement therapy and prostate/seminal vesicle volume in Klinfelter's syndrome. Arch Androl 1989; 22: 245–249
   PubMed Web of Science ®Google Scholar
• Seeman E, Melton L J, III, O'Fallow W M, Riggs B L. Risk factors for spinal osteoporosis in men. Am J Med 1983; 75: 977–983
   PubMed Web of Science ®Google Scholar
• Skakkbaek E N, Bancroft J, Davidson D W, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double-blind controlled study. Clin Endocrinol (Oxf) 1981; 14: 49–61
   PubMed Web of Science ®Google Scholar
• Snyder P J, Lawrence D A. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980; 51: 1335–1339
   PubMed Web of Science ®Google Scholar
• Sokol R Z, Palacios A, Campfield L A, Saul C, Swerdloff R S. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 1982; 37: 425–430
   PubMed Web of Science ®Google Scholar
• Stamper M J, Colditz G A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47–63
   PubMed Web of Science ®Google Scholar
• Tenover J S. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092–1098
   PubMed Web of Science ®Google Scholar
• Thompson P D, Cullinane E M, Sady S P, Chenevert C, Saritelly A L, Sadi M A, Herbert P N. Contrasting effects of testosterone and stanozolol on serum lipoproteins levels. JAMA 1989; 261: 1165–1168
   PubMed Web of Science ®Google Scholar
• Urban R J, Bodenburg Y H, Gilkison C, Foxworth J, Coggan A R, Wolfe R R, Ferrando A. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269: E820–E826
   PubMed Web of Science ®Google Scholar
• Veldhuis J D, Urban R J, Lizarralde G, Jonhson M L, Iranmanesh A. Attenuation of luteinizing hormone secretory burst amplitude as a proximate basis for the hypoandrogenism of healthy aging in men. J Clin Endocrinol Metab 1992; 75: 707–713
   PubMed Web of Science ®Google Scholar
• Vermeulen A. Androgen in the aging male. J Clin Endocrinol Metab 1991; 73: 221–224
   PubMed Web of Science ®Google Scholar
• Walsh P C. Human benign prostatic hyperplasia: etiological considerations. Proc Clin Biol Res 1984; 145: 1–25
   PubMedGoogle Scholar
• Wang C, Eyre D R, Clark R, Kleinberg D, Newman C, Iranmanesh A, Veldhuis J, Dudley R E, Berman N, Davidson T, Barstow T J, Sinow R, Alexander G, Swerdloff R S. Sublingual testosterone replacement improves muscle mass and strength, decrease bone resorption, and increases bone formation markers in hypogonadal men. J Clin Endocrinol Metab 1996; 81: 3854–3662
   Web of Science ®Google Scholar
• Welle S, Josefowicz R, Forbes G, Gringgs R C. Effects of testosterone on metabolic rate and body composition in normal men with muscular dystrophy. J Clin Endocrinol Metab 1992; 74: 332–335
   PubMed Web of Science ®Google Scholar
• Westaby D, Ogle S J, Paradinas F J, Randell J B, Murray-Lyon M L. Liver damage from long-term methyltestosterone. Lancet 1977; 2: 261–263
   Web of Science ®Google Scholar
• Winters S J, Troen P. Episodic luteinizing hormone (LH) secretion and the response of LH and follicle-stimulating hormone to LH-releasing hormone in aged men: evidence for coexistent primary testicular insuffciency and impairment in gonadotropin secretion. J Clin Endocrinol Metab 1982; 55: 560–565
   PubMed Web of Science ®Google Scholar
• Wong F HW, Pun K K, Wang C. Lost of bone mass in patients with Klinefelter's syndrome despite sufficient testosterone replacement. Osteoporo Int 1993; 7: 281–287
   Google Scholar
• Young N R, Baker H WG, Liu G, Seeman E. Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception. J Clin Endocrinol Metab 1993; 77: 1028–1032
   PubMed Web of Science ®Google Scholar
• Zgliczynski S, Ossowaki M, Slowinska-Srzednicka J, Brzdnicka A, Zgliczynski W, Soszynski P, Chotkowska E, Srzednicki M, Sadowaki Z. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atheroesclerosis 1996; 21: 35–43
   Google Scholar
• Zmuda J M, Fahrenbach M C, Younkin B T, Bausserman L, Terry R B, Catlin D H, Thompson P D. The effect of testosterone aromatization of high-density lipoprotein cholesterol levels and post-heparin lipolytic activity. Metabolism 1993; 42: 446–450
   PubMed Web of Science ®Google Scholar